Rabacfosadine is a novel acyclic nucleotide analogue that was designed to target and attack cancerous lymphoma cells. It has demonstrated anti-cancer activity in dogs with lymphoma, and is currently being evaluated in a pilot safety study in cats with lymphoma. Keep Reading

VDC-597 for Various Cancers

VDC-597 is an orally available, dual-acting inhibitor of PI3K and mTOR proteins, both of which are implicated in many types of cancers, including sarcomas, lymphoma and solid tumors… Keep Reading